Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer

@inproceedings{Hosmer2010DevelopmentAV,
  title={Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer},
  author={Wylie D Hosmer and Jennifer L. Malin and Mitchell D. Wong},
  booktitle={Supportive Care in Cancer},
  year={2010}
}
Current guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSF) when febrile neutropenia (FN) risk is greater than 20%. Advanced age is a risk factor for FN; however, little is known about the impact of other factors on the incidence of FN in an older population. We analyzed SEER-Medicare data (1994–2005) to develop and validate a prediction model for hospitalization with fever, infection, or neutropenia occurring after chemotherapy initiation for patients with… CONTINUE READING
23 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

A risk model for first cycle of febrile neutropenia in cancer patients receiving systemic chemotherapy

  • G Lyman, J Crawford, D Wolff
  • J Clin Oncol 23:759s
  • 2005
2 Excerpts

Riskmodels for predicting chemotherapy-induced neutropenia

  • LymanGH, LymanCH, O Agboola
  • Oncologist
  • 2005
3 Excerpts

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

  • LymanGH, DC Dale, J Friedberg
  • J Clin Oncol
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…